Key terms
About EDIT
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EDIT news
May 10
6:08am ET
Editas announces preclinical data from in vivo gene editing medicines
May 10
1:41am ET
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
May 10
1:32am ET
Editas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal Prudence
May 09
7:56am ET
Oppenheimer Remains a Hold on Editas Medicine (EDIT)
May 09
6:49am ET
Editas Medicine (EDIT) Receives a Hold from RBC Capital
May 09
6:26am ET
Editas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Rating
May 09
6:07am ET
Editas Medicine price target lowered to $15 from $16 at Citi
May 09
5:35am ET
Maintaining a Hold: Editas Medicine Awaits Key Clinical Trial Results and Market Positioning
May 09
5:20am ET
Buy Rating for Editas Medicine: Promising Trials and Solid Financial Footing Propel Growth Outlook
May 09
5:00am ET
Editas Medicine price target lowered to $9 from $11 at Barclays
May 09
3:30am ET
Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT), Arcus Biosciences (RCUS) and Maravai Lifesciences Holdings (MRVI)
May 08
6:25pm ET
Editas Medicine upgraded to Equal Weight from Underweight at Morgan Stanley
May 08
7:08am ET
Editas Medicine reports Q1 EPS (76c), consensus (66c)
May 01
8:18am ET
Editas Medicine, Bristol Myers extend alpha-beta T cell collaboration
Apr 22
4:55am ET
Editas Medicine management to meet with Oppenheimer
Apr 19
4:36pm ET
Editas Medicine management to meet with Oppenheimer
Mar 05
7:25am ET
Editas Medicine (EDIT) Receives a New Rating from a Top Analyst
Mar 01
1:17am ET
Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism
Mar 01
1:06am ET
Editas Medicine: Balanced Prospects and a Hold Rating with Modest Price Target Increase
Feb 29
8:07am ET
Oppenheimer Sticks to Its Hold Rating for Editas Medicine (EDIT)
Feb 29
7:19am ET
RBC Capital Reaffirms Their Hold Rating on Editas Medicine (EDIT)
Feb 29
6:28am ET
Editas Medicine price target raised to $16 from $11 at Citi
Feb 29
5:45am ET
Editas Medicine price target raised to $11 from $10 at Barclays
Feb 29
5:43am ET
Hold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potential
Feb 29
5:41am ET
Buy Recommendation for Editas Medicine Backed by Strong SCD Treatment Outlook and Solid Financials
Feb 29
2:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX)
Feb 28
5:28pm ET
Editas Medicine files automatic mixed securities shelf
Feb 28
12:15pm ET
TD Cowen Sticks to Its Buy Rating for Editas Medicine (EDIT)
Feb 28
7:03am ET
Editas Medicine expects cash to fund operations into 2026
Feb 28
7:02am ET
Editas Medicine reports Q4 EPS (23c), consensus (54c)
No recent press releases are available for EDIT
EDIT Financials
Key terms
Ad Feedback
EDIT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EDIT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range